Hormone receptor-positive breast cancer

This phase III trial tests whether taking letrozole continuously for five years is better than taking it in cycles with breaks, for postmenopausal women who have already had 4 to 6 years of hormone therapy for early-stage, hormone-receptor-positive breast cancer. Letrozole works …

This study tests whether giving 6 months of hormone therapy before surgery helps remove all cancer cells in women with early-stage, estrogen-positive breast cancer. It involves 8 postmenopausal women with low-risk, node-negative tumors. The goal is to see if this approach leads t…

This phase III trial asks whether adding bevacizumab to standard hormone therapy (tamoxifen or letrozole) helps women with hormone receptor-positive advanced breast cancer live longer without the disease worsening. Hormone therapy blocks estrogen, which fuels tumor growth, while …

This phase 2 study tests a new drug called SKB264, alone or with another drug KL-A167, in 175 people with advanced HER2-negative breast cancer that hasn't been treated before. The goal is to see if the combination is safe and can shrink tumors. Participants are split into groups …

This study looked at whether shutting down the ovaries (ovarian suppression) combined with hormone therapy (tamoxifen or exemestane) could better prevent breast cancer from coming back in premenopausal women with hormone-sensitive breast cancer. Over 3,000 women who had surgery t…

This trial is testing whether combining palbociclib and fulvestrant can help postmenopausal women with a specific type of advanced breast cancer (ER+/HER2-) that has stopped responding to prior treatments. The study aims to see how long the cancer stays under control and to look …

This completed study examined the safety and effectiveness of Ibrance (palbociclib) in women with advanced or metastatic breast cancer using a large real-world database. Researchers looked at side effects and how well the drug worked in everyday practice. The study included adult…

This trial is testing whether adding an experimental drug called BYL719 to standard hormone therapy (letrozole) can better fight hormone receptor-positive metastatic breast cancer in post-menopausal women. BYL719 targets a protein that helps cancer cells grow, while letrozole blo…

This early-stage trial is testing an experimental drug called BEBT-209 in women with advanced HR+/HER2- breast cancer. The study aims to find the safest dose and see how well the drug works, both on its own and when combined with standard hormone therapies like letrozole or fulve…

This study tests whether a combination of ribociclib (a targeted pill) and hormone therapy can shrink tumors faster and more effectively than chemotherapy in women with a fast-growing type of advanced breast cancer (HR-positive, HER2-negative). Participants receive ribociclib plu…

This study looked at the safety and effectiveness of a drug called ribociclib combined with hormone therapy for people with a certain type of advanced breast cancer (HR+/HER2-). Researchers collected real-world data from 175 patients in the Middle East to track side effects and h…

This phase 2 trial tested whether adding the experimental drug PF-07220060 to the standard hormone therapy letrozole works better than letrozole alone in postmenopausal women with a common type of breast cancer (HR+/HER2-). The 121 participants took the pills for 14 days before t…

This study tested the safety of combining two drugs, alpelisib and fulvestrant, in 40 men and post-menopausal women with a certain type of advanced breast cancer (HR+, HER2-, with a PIK3CA mutation) that had worsened after hormone therapy. The goal was to track side effects. The …

This study tested whether adding the drug ribociclib to standard hormone therapy helps slow the growth of advanced breast cancer in Chinese women. About 327 women with a specific type of breast cancer (HR+, HER2-) took part. The main goal was to see how long the cancer stayed und…

This early-phase study tested a combination of two drugs—capecitabine (a chemotherapy pill) and cemiplimab (an immunotherapy)—in 13 people with hormone receptor-positive breast cancer that had spread. The main goal was to find the safest dose and see if the combo could shrink tum…

This study tested a new drug called CT7001, alone or with other cancer treatments, in 124 people with advanced solid tumors like breast and prostate cancer. The main goal was to check safety and side effects. The drug is taken by mouth and aims to control the disease, not cure it…

This Phase 1 trial tested an investigational oral drug called CFI-402257 in 52 people with advanced solid tumors, including breast cancer, that had stopped responding to standard treatments. The main goal was to find a safe dose and check how the drug moves through the body. It w…

This study tested a new oral drug called BGB-43395 in 33 Chinese patients with advanced or metastatic HR+/HER2- breast cancer and other solid tumors. The drug blocks a protein (CDK4) that helps cancer cells grow. The goal was to find a safe dose and see if it can shrink tumors wh…

This early-phase study tested a new drug called ONO-4578 combined with standard hormone therapy and targeted drugs (letrozole plus palbociclib or abemaciclib) in 46 postmenopausal women with advanced or recurrent hormone receptor-positive, HER2-negative breast cancer. The main go…

This early-phase trial tested two oral drugs, dalpiciclib and chidamide, in 22 people with HR+/HER2- advanced breast cancer whose disease had worsened after CDK4/6 inhibitor therapy. The main goal was to find the safest dose. Researchers also looked at how well the combination sh…

This study tested a chemotherapy drug called trifluridine/tipiracil in 52 women with advanced ER-positive, HER2-negative breast cancer that had already been treated with other chemotherapies. The goal was to see if the drug could slow cancer growth and improve quality of life. Th…

This study tested whether adding palbociclib (a targeted cancer drug) to standard hormone therapy (letrozole) helps Asian postmenopausal women with a certain type of advanced breast cancer (ER+/HER2-). The trial involved 340 women who had not received prior treatment for their ad…

This study tested a new oral drug called OP-1250 in 153 adults with advanced or metastatic hormone-receptor-positive, HER2-negative breast cancer. The drug works by blocking estrogen receptors more completely than current therapies. The trial aimed to find the best dose, check sa…

This study tested whether adding the immunotherapy drug atezolizumab to standard chemotherapy (bevacizumab and paclitaxel) helps people with a certain type of advanced breast cancer (HR-positive, HER2-negative). The trial enrolled 281 participants whose cancer had spread or could…

This study tested a new drug combination (fluzoparib plus chemotherapy) given before surgery to 28 women with a specific type of early breast cancer (HR+/HER2- with HRD). The goal was to see if it could shrink tumors more effectively. The treatment was given over 8 cycles, and th…

This study tested a new drug (TQB3616) combined with fulvestrant in 122 people with a type of advanced breast cancer (HR-positive, HER2-negative). The goal was to see if the combination could shrink tumors or slow the cancer's growth. Participants had either received one prior tr…

This study tested whether adding the experimental drug TQB3616 to standard hormone therapy (fulvestrant) can help slow cancer growth in people with a common type of advanced breast cancer (HR-positive, HER2-negative). About 293 women took part, receiving either the drug combo or …

This study tested a new two-drug combination (samuraciclib and elacestrant) in 49 adults with a common type of advanced breast cancer (HR+/HER2-). The goal was to find a safe dose and see if it can slow the cancer's growth. Participants had already tried other treatments and thei…

This study tested a new drug called giredestrant against the standard drug tamoxifen in 92 premenopausal women with a common type of early breast cancer. Participants took the medication for 15 days before their planned surgery. The goal was to see how well each drug slowed tumor…

This study tested a new drug called DF1001 in 270 adults with advanced solid tumors that have spread or cannot be removed. The drug works by helping the body's immune cells attack cancer cells. The trial first found the safest dose, then tested it alone or with other cancer drugs…

This phase 2 study tested whether adding ganetespib, an experimental drug that blocks a protein called HSP90, to the standard hormone therapy fulvestrant could help people with hormone receptor-positive metastatic breast cancer that has stopped responding to hormone treatment. Th…

This study tested whether adding a low-dose chemotherapy pill (capecitabine) to standard hormone therapy (aromatase inhibitor) helps women with a common type of advanced breast cancer live longer without the disease getting worse. The trial involved 263 women who had not received…

This Phase 3 trial tested two hormone therapies, fulvestrant (Faslodex) and anastrozole (Arimidex), in 462 postmenopausal women with advanced hormone receptor-positive breast cancer who had not received prior hormone treatment. The study compared how long each drug kept the cance…

This study tested a new drug called giredestrant, alone or with triptorelin, against a standard treatment (anastrozole plus triptorelin) in 231 premenopausal women with early-stage, hormone-sensitive breast cancer. The goal was to see how well the drugs slow tumor growth before s…

This early-stage study tested the drug palbociclib (combined with letrozole) in 26 postmenopausal Chinese women with a specific type of advanced breast cancer (ER+, HER2-). The main goal was to see how the drug moves through the body and to check for safety. The study is complete…

This study tested whether adding the drug darsilide to standard hormone therapy (exemestane and goserelin) can shrink tumors in premenopausal women with HR-positive, HER2-negative breast cancer. The 119 participants had not responded fully to initial chemotherapy. The main goal w…

This study tested a combination of three drugs (letrozole, everolimus, and TRC105) given before surgery to postmenopausal women with hormone-receptor-positive, HER2-negative breast cancer. The goal was to see if the combo was safe and could shrink tumors. Fifteen women with stage…

This early-phase study tested two drugs, abemaciclib and niraparib, given together before surgery in 8 people with hormone receptor-positive, HER2-negative breast cancer. The goal was to find the best dose and see if the combination could shrink tumors safely. The study focused o…

This study looked at how well the drug ribociclib works in real-world settings for Indian women with a common type of advanced breast cancer (HR+, HER2-). Researchers reviewed medical records of 335 patients treated across 18 sites in India. The goal was to measure how long the d…

This study tested a combination of two drugs, palbociclib and tamoxifen, as the first treatment for people with a certain type of advanced breast cancer (HR-positive, HER2-negative). The goal was to see how long the cancer could be kept from growing. 49 participants took both pil…

This study tested a drug called alpelisib combined with hormone therapy (fulvestrant or letrozole) in 383 people with advanced breast cancer that has a specific genetic change (PIK3CA mutation). The goal was to see how many patients were alive without their cancer getting worse a…

This early-phase trial tested a combination of three drugs—olaparib, palbociclib, and fulvestrant—in 9 people with BRCA-mutated, hormone-positive, HER2-negative metastatic breast cancer. The main goal was to see if the combination is safe. Researchers also looked at how long the …

This study tested whether adding the experimental drug samuraciclib to standard hormone therapy (fulvestrant) works better than fulvestrant alone for people with advanced HR+/HER2- breast cancer. The trial enrolled 60 adults whose cancer had worsened despite prior treatment. Rese…

This early-stage trial tested an experimental drug called Z-Endoxifen in 40 adults with hormone receptor-positive cancers (like breast, ovarian, or desmoid tumors) that had stopped responding to standard treatments. Z-Endoxifen is a direct form of tamoxifen's active ingredient, b…

This phase II trial tested a combination of hormone therapy drugs (fulvestrant or an aromatase inhibitor) plus palbociclib in 14 elderly patients with hormone-responsive breast cancer who either had inoperable tumors or were too frail for surgery. The goal was to see if this drug…

This study tested two treatment plans for people with advanced HR-positive, HER2-negative breast cancer that is aggressive. One group received a drug called abemaciclib plus hormone therapy. The other group started with a short course of chemotherapy, then switched to abemaciclib…

This early-phase study tested a new drug called ABBV-155, given alone or with standard chemotherapy (paclitaxel or docetaxel), in 168 adults with advanced solid tumors that had come back or stopped responding to treatment. The main goal was to find a safe dose and check for early…

This early-stage study tested the safety of combining the drug rucaparib with standard radiation therapy in 31 women with triple-negative breast cancer who still had cancer cells after chemotherapy and surgery. The goal was to find a safe dose and see if the combination could be …

This phase 2 trial tested whether adding loperamide (Imodium) and a white blood cell booster (G-CSF) could reduce severe diarrhea and low white blood cell counts caused by the drug Trodelvy in people with advanced breast cancer. Fifty patients with metastatic triple-negative or l…

This study tested several immunotherapy-based drug combinations in 144 people with advanced hormone receptor-positive, HER2-negative breast cancer that had worsened after initial treatment. Participants received atezolizumab (Tecentriq) along with other drugs like bevacizumab or …

This study tested a combination of two drugs, crizotinib and fulvestrant, in 33 people with advanced lobular breast cancer that had lost a protein called E-cadherin. It also tested crizotinib alone in people with diffuse gastric cancer, triple-negative lobular breast cancer, or o…

This early-phase study tested a new oral drug called H3B-6545 in 33 Japanese women with a common type of breast cancer (ER-positive, HER2-negative). The main goal was to see if the drug is safe and tolerable, and to find the right dose for Japanese patients. Participants had alre…

This study tested a lower starting dose (400 mg) of the targeted drug ribociclib combined with standard hormone therapy (letrozole or anastrozole) in 376 women with advanced hormone receptor-positive, HER2-negative breast cancer. The goal was to see if the lower dose could contro…

This early-phase trial tested a new combination of two drugs (ARV-471 and everolimus) in 32 people with a common type of advanced breast cancer (ER+/HER2-). The main goals were to find the safest dose and check for side effects. Researchers also looked at whether the tumors shran…

This completed Phase 2 trial tested whether adding atorvastatin (a cholesterol-lowering drug) to standard hormone therapy (letrozole or fulvestrant) could improve outcomes in 126 women with advanced, hormone-receptor-positive breast cancer. The main goal was to see if the combina…

This early-phase trial is testing a new radioactive imaging agent called 68Ga-R10602 in 36 people with hormone receptor-positive breast cancer that has come back or spread. The agent is designed to light up tumors on PET/CT scans. The main goals are to check safety and see how we…

This study tested whether a gene test called MammaPrint can help doctors decide which breast cancer patients need chemotherapy before surgery. The goal is to shrink tumors enough so that patients can have less invasive surgery, like a lumpectomy instead of a mastectomy. The study…

This study tested a new blood test (liquid biopsy) that looks for cancer DNA in the blood of 30 women with advanced ER+/HER2- breast cancer. The goal was to see if the test can accurately find cancer mutations without needing a traditional tissue biopsy. The results will help doc…

This study tested whether acupuncture can reduce hot flashes in women with hormone-positive breast cancer who are on hormonal therapy. 84 participants were randomly assigned to receive either acupuncture or usual care. The main goal was to see if acupuncture lowered hot flash sco…

This study tested a brief, nurse-led videoconference program designed to help breast cancer survivors who were hesitant or delayed in starting recommended hormone therapy. The program aimed to address cultural and personal concerns. Researchers measured how many people enrolled, …

This study tested whether a 12-week home-based program of walking and resistance band exercises could improve physical fitness, fatigue, and quality of life for 36 breast cancer patients in Indonesia. Participants used pedometers and resistance bands at home, with weekly phone ch…

This study looked at whether taking hormone therapy for breast cancer in the morning or evening reduces side effects and helps patients stay on treatment. 245 women with early-stage breast cancer were randomly assigned to take their medication either within an hour of waking or w…

This study tested a special pain program for breast cancer survivors who have joint and muscle pain from taking aromatase inhibitors (hormone therapy). The program combined education, coping skills, and gentle movement to help reduce pain, improve mood, and make it easier to stic…

This pilot study tested a collagen-based food supplement (Tenflex®) in 30 women with breast cancer who had joint pain from hormone therapy (aromatase inhibitors). The goal was to see if pain levels improved over 12 weeks. The supplement is already sold as a food product, so this …

This study observed over 2,400 women in Russia with advanced HR+/HER2- breast cancer to see how well different treatments work in everyday medical practice. Researchers tracked how long patients stayed on their therapy before it stopped working or caused side effects. The goal wa…

This study looks back at medical records to see how ribociclib, a CDK4/6 inhibitor used for hormone receptor-positive, HER2-negative metastatic breast cancer, is prescribed and tolerated in older adults (65 and over) and Black/African American patients. These groups are often und…

This study observes how Canadian women with a specific type of advanced breast cancer (HR+/HER2-) use the drug palbociclib (Ibrance) as their first treatment. Researchers will measure how long patients stay on the drug and look at treatment patterns in real-world settings, outsid…

This study follows 450 premenopausal women with early-stage hormone-positive breast cancer in Italy. Researchers want to see how adding triptorelin to standard hormone therapy affects quality of life and hormone levels. The goal is to better understand the real-world impact of tr…

This study looks at medical records from across Europe to see how well a drug combination (palbociclib plus an aromatase inhibitor) works as a first treatment for people with a common type of advanced breast cancer (HR+/HER2-). Researchers want to understand how long the treatmen…

This study looked at medical records of 204 Brazilian adults with a specific type of advanced breast cancer (HR+/HER2-). The goal was to see which treatments doctors actually use and how patients fare. No new treatments were tested; instead, researchers collected information to u…

This study looks at medical records from 750 people with a common type of early breast cancer (HR+/HER2-). It aims to understand how doctors treat these patients in real life, especially after newer targeted drugs called CDK4/6 inhibitors became available. By analyzing treatment …

This study explored whether a simple blood test measuring the neutrophil-to-lymphocyte ratio (NLR) can help predict how well women with advanced breast cancer respond to a common treatment (CDK4/6 inhibitors plus hormone therapy). Researchers followed 165 patients starting this t…

This study looked at 185 people with a common type of advanced breast cancer (HR+/HER2-) in Africa and the Middle East who were starting treatment with palbociclib combined with hormone therapy. Researchers tracked how long the cancer stayed under control and how patients felt ov…

This study examined the vaginal microbiome—the community of bacteria and other microbes—in 35 women with breast cancer who were receiving hormone therapy. The goal was to see if certain bacteria are linked to vaginal dryness and sexual health. Researchers collected vaginal swabs …

This completed study looked at 121 women in Brazil with a certain type of advanced breast cancer (HR+/HER2-). Researchers tracked how doctors prescribed palbociclib combined with other drugs in everyday practice, not in a strict trial setting. The goal was to describe patient bac…

This completed study looked at medical records of 258 adults in Saudi Arabia, UAE, and other Gulf countries who received palbociclib (a targeted cancer pill) combined with hormone therapy for advanced HR+/HER2- breast cancer. Researchers aimed to describe patient characteristics,…

This completed study looked at over 6,000 people with advanced breast cancer to see if information from electronic health records could match the results of a famous clinical trial called PALOMA-2. The goal was not to test a new drug, but to learn whether real-world data can be t…

This study looked at how a person's genes and drug levels in the blood affect hormone therapy for breast cancer. It included 2000 women with hormone-sensitive breast cancer who were already scheduled for adjuvant hormone therapy. Researchers measured drug levels and genetic marke…

This completed study looked at 480 patients with HR+, HER2- metastatic breast cancer who were treated with CDK4/6 inhibitors as their first therapy. Researchers examined patient profiles, treatment patterns, and outcomes in everyday clinical practice. The goal was to understand h…

This study looked at whether a tumor gene test called the 21 gene Recurrence Score (OncotypeDx) changes doctors' recommendations for chemotherapy in women with early-stage, hormone receptor-positive breast cancer that has spread to lymph nodes. Researchers tracked how often chemo…

This study looked back at medical records of 693 Japanese patients with a certain type of advanced breast cancer (HR+/HER2-) who received palbociclib plus endocrine therapy as their first or second treatment. Researchers measured how long patients lived without the cancer getting…

This study observed 440 adults in Poland with advanced HR+ HER2- breast cancer to understand how doctors treat the disease in everyday practice. Researchers tracked treatment choices, changes over one year, and how they relate to patient characteristics and guidelines. The goal w…

This study looked at medical records from over 218,000 adults in England with a common type of breast cancer (HR+/HER2-). Researchers tracked which treatments people received, how the disease progressed over time, and how healthcare resources were used. The goal was to understand…

This study examined how well CDK4/6 inhibitors (a type of targeted therapy) work for people with advanced breast cancer in Egypt. Researchers looked at 206 patients to measure how long the drugs kept cancer from growing, side effects, and overall costs. The goal was to see if the…

This completed Phase 2 trial enrolled 61 postmenopausal women with operable, hormone-sensitive breast cancer. Participants took letrozole for 7 to 30 days before their scheduled surgery. The goal was to measure changes in a tumor marker called Ki67 to see which cancers are highly…

This study tested whether a special survivorship clinic, combined with an app for reporting symptoms, is practical for women who have finished curative treatment for early-stage breast, cervical, or endometrial cancer. Two hundred women visited the clinic at the start and end of …

This study reviewed medical records of women with advanced or metastatic HR+/HER2- breast cancer who received Palbociclib combined with hormone therapy in community clinics. The goal was to see how doctors actually prescribe these drugs, how long patients stay on treatment, and w…

This completed observational study in India enrolled 595 people with HR-positive, HER2-negative advanced or metastatic breast cancer who were already taking alpelisib plus fulvestrant. Researchers looked for PIK3CA gene mutations in tumors and tracked how well the cancer responde…

This study interviewed 48 adults with HR+/HER2- metastatic breast cancer who had taken capivasertib + fulvestrant for at least one week. The goal was to learn about their attitudes, experiences, and any side effects related to the treatment schedule. No new drugs were given; it w…

This study looked at whether adding a drug that targets specific genetic changes in breast tumors could slow cancer growth more than standard hormone therapy alone. It involved 19 people with ER-positive, HER2-negative breast cancer who received treatment before surgery. The goal…

This pilot study tested a combination of chemotherapy (Nab-Paclitaxel) and immunotherapy (Pembrolizumab) in 32 women with hormone receptor-positive, HER2-negative breast cancer before surgery. The main goal was to see how the treatment changed a biomarker called PD-L1 in tumor sa…

This study observed over 2,600 women in Germany with a common type of advanced breast cancer (HR+/HER2-). Researchers compared how long the cancer stayed under control when women started treatment with a drug combo (ribociclib plus hormone therapy) versus other hormone therapies …

This study involved 562 premenopausal women in China with hormone receptor-positive breast cancer who received a GnRHa injection to suppress ovarian function after surgery. Researchers measured their quality of life and how well they followed the treatment plan using questionnair…

This completed study in Japan reviewed medical records of 42 patients with HR+/HER2- advanced breast cancer who had been treated with palbociclib plus letrozole. The goal was to see how long patients lived after starting this treatment. It was a follow-up to an earlier phase 2 st…

This study tested whether an automated system can grow cancer cells from patient samples (blood, fluid, or tumor tissue) inside chicken eggs. Researchers aimed to see if at least half of the samples would successfully grow. The goal is to create a better, cheaper way to study can…

This study looked at medical records of 779 older adults (65+) with a certain type of advanced breast cancer (HR+/HER2-). It compared survival in those who received a combination of the drug palbociclib plus hormone therapy versus hormone therapy alone. The goal was to see which …

This completed study looked at how CDK4/6 inhibitors are used in everyday practice for advanced breast cancer in Portugal. Researchers analyzed data from 16 public hospitals to understand dosing patterns, treatment duration, and how often doses were adjusted. The study included n…

This completed study analyzed data from 1,415 patients with HR-positive, HER2-negative metastatic breast cancer in the United States. Researchers looked at what happened after patients progressed on their first-line treatment (endocrine therapy plus a CDK4/6 inhibitor) and starte…